BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu X, Qu D, Weygant N, Peng J, Houchen CW. Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments. Cancers (Basel) 2020;12:E274. [PMID: 31979136 DOI: 10.3390/cancers12020274] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang Z, Chen S, Wang G, Li S, Qin X. CDCA3 Is a Novel Prognostic Biomarker Associated with Immune Infiltration in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:6622437. [PMID: 33604380 DOI: 10.1155/2021/6622437] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Wei J, Gao X, Qin Y, Liu T, Kang Y. An Iron Metabolism-Related SLC22A17 for the Prognostic Value of Gastric Cancer. Onco Targets Ther 2020;13:12763-75. [PMID: 33363382 DOI: 10.2147/OTT.S287811] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Marin JJG, Perez-Silva L, Macias RIR, Asensio M, Peleteiro-Vigil A, Sanchez-Martin A, Cives-Losada C, Sanchon-Sanchez P, Sanchez De Blas B, Herraez E, Briz O, Lozano E. Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma. Cancers (Basel) 2020;12:E2116. [PMID: 32751679 DOI: 10.3390/cancers12082116] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Vijai M, Baba M, Ramalingam S, Thiyagaraj A. DCLK1 and its interaction partners: An effective therapeutic target for colorectal cancer. Oncol Lett 2021;22:850. [PMID: 34733368 DOI: 10.3892/ol.2021.13111] [Reference Citation Analysis]
5 Cai Z, Yu C, Li S, Wang C, Fan Y, Ji Q, Chen F, Li W. A Novel Classification of Glioma Subgroup, Which Is Highly Correlated With the Clinical Characteristics and Tumor Tissue Characteristics, Based on the Expression Levels of Gβ and Gγ Genes. Front Oncol 2021;11:685823. [PMID: 34222011 DOI: 10.3389/fonc.2021.685823] [Reference Citation Analysis]
6 Song D, Wang Y, Zhu K, Tian L, Gao Q, Zhou J, Fan J, Wang X. DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. World J Surg Oncol 2020;18:176. [PMID: 32690026 DOI: 10.1186/s12957-020-01953-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
7 Tsuchiya H, Shiota G. Immune evasion by cancer stem cells. Regen Ther 2021;17:20-33. [PMID: 33778133 DOI: 10.1016/j.reth.2021.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu X, Chen F, Li W. Elevated expression of DOK3 indicates high suppressive immune cell infiltration and unfavorable prognosis of gliomas. Int Immunopharmacol 2020;83:106400. [PMID: 32193105 DOI: 10.1016/j.intimp.2020.106400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Jayaraman S, Gnanasampanthapandian D, Rajasingh J, Palaniyandi K. Stem Cell-Derived Exosomes Potential Therapeutic Roles in Cardiovascular Diseases. Front Cardiovasc Med 2021;8:723236. [PMID: 34447796 DOI: 10.3389/fcvm.2021.723236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhao Y, Zhang H, Ju Q, Li X, Zheng Y. Comprehensive Analysis of Survival-Related lncRNAs, miRNAs, and mRNAs Forming a Competing Endogenous RNA Network in Gastric Cancer. Front Genet 2021;12:610501. [PMID: 33737947 DOI: 10.3389/fgene.2021.610501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chen P, Hsu WH, Han J, Xia Y, DePinho RA. Cancer Stemness Meets Immunity: From Mechanism to Therapy. Cell Rep 2021;34:108597. [PMID: 33406434 DOI: 10.1016/j.celrep.2020.108597] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
12 Liu Y, Ferguson FM, Li L, Kuljanin M, Mills CE, Subramanian K, Harshbarger W, Gondi S, Wang J, Sorger PK, Mancias JD, Gray NS, Westover KD. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chem Biol 2020;27:1229-1240.e4. [PMID: 32755567 DOI: 10.1016/j.chembiol.2020.07.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Fang L, Maly DJ. The Right Tool for the Job: A Chemical and Genetic Toolkit for Interrogating DCLK1 Function. Cell Chem Biol 2020;27:1221-3. [PMID: 33065025 DOI: 10.1016/j.chembiol.2020.09.007] [Reference Citation Analysis]
14 Saunders AS, Bender DE, Ray AL, Wu X, Morris KT. Colony-stimulating factor 3 signaling in colon and rectal cancers: Immune response and CMS classification in TCGA data. PLoS One 2021;16:e0247233. [PMID: 33606788 DOI: 10.1371/journal.pone.0247233] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Zeng F, Li G, Liu X, Zhang K, Huang H, Jiang T, Zhang Y. Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma. Oncologist 2021;26:e1460-9. [PMID: 33687124 DOI: 10.1002/onco.13750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Cao Z, Weygant N, Chandrakesan P, Houchen CW, Peng J, Qu D. Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment. Cancers (Basel) 2020;12:E3801. [PMID: 33348546 DOI: 10.3390/cancers12123801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Carli ALE, Afshar-Sterle S, Rai A, Fang H, O'Keefe R, Tse J, Ferguson FM, Gray NS, Ernst M, Greening DW, Buchert M. Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells. Proteomics 2021;21:e2000098. [PMID: 33991177 DOI: 10.1002/pmic.202000098] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Meadows V, Francis H. Doublecortin-Like Kinase Protein 1 in Cholangiocarcinoma: Is This the Biomarker and Target We Have Been Looking For? Hepatology 2021;73:4-6. [PMID: 33179783 DOI: 10.1002/hep.31630] [Reference Citation Analysis]
19 Chen K, Zhu S, Yu W, Xia Y, Xing J, Geng J, Cheng F. Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer. Front Oncol 2022;12:774307. [DOI: 10.3389/fonc.2022.774307] [Reference Citation Analysis]
20 Broner EC, Trujillo JA, Korzinkin M, Subbannayya T, Agrawal N, Ozerov IV, Zhavoronkov A, Rooper L, Kotlov N, Shen L, Pearson AT, Rosenberg AJ, Savage PA, Mishra V, Chatterjee A, Sidransky D, Izumchenko E. Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma. Front Oncol 2021;11:677051. [PMID: 34336664 DOI: 10.3389/fonc.2021.677051] [Reference Citation Analysis]
21 Ding L, Yang Y, Ge Y, Lu Q, Yan Z, Chen X, Du J, Hafizi S, Xu X, Yao J, Liu J, Cao Z, Weygant N. Inhibition of DCLK1 with DCLK1-IN-1 Suppresses Renal Cell Carcinoma Invasion and Stemness and Promotes Cytotoxic T-Cell-Mediated Anti-Tumor Immunity. Cancers (Basel) 2021;13:5729. [PMID: 34830884 DOI: 10.3390/cancers13225729] [Reference Citation Analysis]